FARMERS & MERCHANTS TRUST Co OF LONG BEACH Sells 7,346 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

FARMERS & MERCHANTS TRUST Co OF LONG BEACH decreased its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 72.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,755 shares of the medical equipment provider’s stock after selling 7,346 shares during the period. FARMERS & MERCHANTS TRUST Co OF LONG BEACH’s holdings in Zimmer Biomet were worth $297,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in ZBH. Crewe Advisors LLC acquired a new stake in Zimmer Biomet during the 1st quarter worth about $31,000. Ables Iannone Moore & Associates Inc. acquired a new stake in shares of Zimmer Biomet in the 4th quarter valued at about $30,000. J.Safra Asset Management Corp increased its position in Zimmer Biomet by 712.1% in the 1st quarter. J.Safra Asset Management Corp now owns 268 shares of the medical equipment provider’s stock valued at $35,000 after buying an additional 235 shares in the last quarter. Bangor Savings Bank acquired a new position in Zimmer Biomet during the 3rd quarter worth approximately $31,000. Finally, Family Firm Inc. acquired a new stake in Zimmer Biomet in the second quarter valued at approximately $33,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Stock Performance

Shares of NYSE ZBH opened at $103.50 on Friday. The stock’s 50-day moving average is $108.37 and its 200 day moving average is $113.31. The stock has a market cap of $21.08 billion, a price-to-earnings ratio of 21.56, a P/E/G ratio of 1.89 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a 1-year low of $101.47 and a 1-year high of $133.90. The company has a current ratio of 1.29, a quick ratio of 0.63 and a debt-to-equity ratio of 0.31.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Wednesday, August 7th. The medical equipment provider reported $2.01 EPS for the quarter, topping the consensus estimate of $1.99 by $0.02. Zimmer Biomet had a net margin of 13.25% and a return on equity of 12.86%. The firm had revenue of $1.94 billion for the quarter, compared to the consensus estimate of $1.94 billion. During the same period last year, the firm posted $1.82 earnings per share. The business’s revenue was up 3.9% compared to the same quarter last year. On average, sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 31st. Investors of record on Monday, September 30th will be issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.93%. The ex-dividend date is Monday, September 30th. Zimmer Biomet’s dividend payout ratio is presently 20.00%.

Wall Street Analysts Forecast Growth

ZBH has been the subject of several research reports. Truist Financial reissued a “hold” rating and issued a $112.00 price target (down previously from $117.00) on shares of Zimmer Biomet in a research report on Friday, September 13th. Evercore ISI decreased their price objective on shares of Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating for the company in a report on Tuesday, October 1st. TD Cowen dropped their target price on shares of Zimmer Biomet from $143.00 to $119.00 and set a “hold” rating on the stock in a research note on Friday, September 6th. Raymond James dropped their price target on shares of Zimmer Biomet from $138.00 to $128.00 and set an “outperform” rating on the stock in a research note on Thursday, August 8th. Finally, Morgan Stanley cut their price target on Zimmer Biomet from $130.00 to $120.00 and set an “equal weight” rating for the company in a report on Monday, July 15th. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Zimmer Biomet presently has a consensus rating of “Hold” and an average target price of $124.53.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.